DuChemBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DuChemBio makes radiopharmaceuticals, specialist drugs that carry radioactive isotopes to diseased tissue in the body, where the radiation either lights up a tumour on a PET-CT scanner or destroys cancer cells directly.
Hospitals and nuclear-medicine departments are the primary users of these prescription-only drugs, which target cancer and brain diseases. Listed on KOSDAQ, Korea's tech and small-cap board, the company holds the broadest portfolio of PET-CT radiopharmaceuticals in Korea and operates over a dozen manufacturing sites, several of which carry pharmaceutical good-manufacturing-practice certification.
Summary is AI-generated and may contain errors · figures from DART filings
DuChemBio completed a full acquisition of radiopharmaceutical R&D specialist Radio D&S Labs Co., Ltd., founded by a nuclear-medicine professor at Seoul Asan Hospital, and plans to transfer its R&D activities to that subsidiary.
DuChemBio in five facts
What does DuChemBio do?
DuChemBio makes radiopharmaceuticals, specialist drugs that carry radioactive isotopes to diseased tissue in the body, where the radiation either lights up a tumour on a PET-CT scanner or destroys cancer cells directly.
Where is DuChemBio listed and in which sector?
DuChemBio (Korean name: 듀켐바이오) trades under KRX code 176750 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is DuChemBio?
Its market capitalisation was US$203.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DuChemBio's latest annual revenue and operating profit?
For fiscal year 2025, DuChemBio reported revenue of US$29.1M, operating profit of US$5.6M and net income of US$4.9M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 8.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Completion report on merger, etc. (merger)
DuChemBio Co., Ltd. completed its small-scale merger absorbing its wholly owned subsidiary Radio D&S Labs Co., Ltd., effective October 2, 2026, with no new shares issued; 142 shareholders holding 59,450 shares (0.21%) filed notices of dissent, and no creditor objections were received.
M&A · Oct 2 - DisclosureSep 4
- Report on large shareholdings (5% rule) (abbreviated)Aug 31
- [Attachment amended] Material event report (merger)M&A · Jul 23
- [Attachment amended] Material event report (merger)M&A · Jul 23
- Material event report (merger)
DuChemBio Co., Ltd. decided to absorb its wholly owned subsidiary Radio D&S Labs Co., Ltd. through a small-scale, no-new-share merger (ratio 1.0000000:0.0000000), with a merger date of October 2, 2026 and no change in DuChemBio's largest shareholder.
M&A · Jul 22 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DuChemBio updated its previously filed consolidated results for FY2025: revenue of US$26.3M (+8.3% year on year), operating profit of US$5.08M (+46.6% year on year) and net income of US$4.42M (−18.9% year on year).
Earnings · Mar 10 · 2 versions